Biomm S.A. (BVMF:BIOM3)
Brazil flag Brazil · Delayed Price · Currency is BRL
7.54
+0.19 (2.59%)
Apr 28, 2026, 5:05 PM GMT-3

Biomm Company Description

Biomm S.A. operates as a biotechnology company in Brazil.

The company offers insulin products for the treatment of diabetes, including AFREZZA, a human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; Lifepen G, a reusable insulin injection pen; and Biopemm, a reusable insulin delivery device for diabetic patients.

It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-stage and metastatic breast cancer and metastatic gastric cancer with HER2-positive tumors; GHEMAXAN, an anticoagulant for the treatment of deep vein thrombosis and pulmonary embolism, unstable angina, and acute myocardial infarction; and RANIVISIO for treating vision problems related to abnormal blood vessel growth or fluid buildup in the retina.

The company was incorporated in 2001 and is based in Nova Lima, Brazil.

Biomm S.A.
Country Brazil
Founded 2001
Industry Biotechnology
Sector Healthcare
Employees 130
CEO Guilherme Maradei

Contact Details

Address:
705 – Lagoa dos Ingleses
Nova Lima, MG 34018-000
Brazil
Phone 55 31 3299 1000
Website biomm.com

Stock Details

Ticker Symbol BIOM3
Exchange Brazil Stock Exchange
Fiscal Year January - December
Reporting Currency BRL
ISIN Number BRBIOMACNOR2
SIC Code 2836

Key Executives

Name Position
Guilherme Maradei Chief Executive Officer and Member of Executive Board
Marcelo Sáfadi Alvares Chief Financial Officer and IR
Francisco Carlos Marques de Freitas Director of Technology and Member of the Executive Board
Francisco Rafael Costa Jr. Commercial Director and Member of Executive Board
Luciano da Silva Machado Operations Director and Member of Executive Board
Nayara Rodrigues de Souza Cruz Accountant